Prevention of perinatal HIV transmission: current status and future developments in anti-retroviral therapy.
Significant progress has been made in the battle against transmission of HIV-1 from mother to infant. Antiretroviral regimens covering the later part of gestation, labour and the first few weeks of neonatal life have shown great efficacy in reducing such transmission. With the advent of combination antiretroviral therapies, transmission rates lower than 2% have been achieved in clinical studies. Elective caesarean delivery has been shown to enhance the benefit of antiretroviral regimens; however, the risks associated with this approach in many resource-poor settings in developing countries limit its role worldwide. Abbreviated antiretroviral regimens covering labour and the first few days of neonatal life have shown considerable promise in the developing world, resulting in 50% reduction in transmission. Several questions and challenges remain, however. Amongst them, choice of the optimal antiretroviral agent(s), evaluation of purely post-exposure neonatal prophylaxis, availability of antiretroviral agents in developing countries, long-term safety of antiretroviral therapy during pregnancy and early neonatal life, and the problem of breastfeeding transmission in the developing world are some issues that need urgent attention.
Kourtis
Athena P
AP
Eastern Virginia Medical School, Norfolk, Virginia, USA. akourti@pol.net
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000821:virology*; D016896:Treatment Outcome
D019380:Anti-HIV Agents